14 results on '"Park, Junsik"'
Search Results
2. Laparoscopic interval debulking surgery following neoadjuvant chemotherapy similar oncologic outcomes to laparotomy for advanced ovarian cancer
3. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
4. Human epidermal growth factor receptor-2 (HER2) receptor expression and its dynamic change in patients with ovarian cancer
5. Dynamic immunological changes on tumor microenvironment during treatment in cervical cancer
6. The feasibility and safety of interval debulking surgery in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy with tremelimumab and durvalumab
7. Differential immune characteristics and anti-PD-1-induced reinvigoration capacity of tumor-infiltrating lymphocytes according to ProMisE classifier in endometrial cancer
8. Immunological characteristics of malignant ascites in newly diagnosed or recurrent epithelial ovarian cancer
9. Potential therapeutic roles of PD-1 blockade in reinvigorating tumor-infiltrating CD8 T cells in patients with BRCA1/2 mutated ovarian cancer
10. Oregovomab and non-platinum chemotherapy in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: a multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6)
11. Circulating tumor DNA as a predictive and prognostic biomarker for BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer receiving triplet maintenance therapy (OPEB-01)
12. Differential implication of PET-CT response and pathologic complete response (pCR) in ovarian cancer patients undergoing neoadjuvant chemotherapy (NAC) with or without immunotherapy
13. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer
14. Different immunological changes in tumor-infiltrating lymphocytes during neoadjuvant chemotherapy with or without tremelimumab and durvalumab in newly diagnosed advanced-stage ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.